All Stories

  1. Global Trends and Projections in Chronic Kidney Disease Burden from Diabetes, Hypertension, and Glomerulonephritis: A Population-Based Study
  2. Microbiota-Targeted Modulation of the Gut–Kidney Axis in Diabetic Kidney Disease: Therapeutic Advances and Future Perspectives
  3. Sterol Regulatory Element-Binding Proteins and Metabolic Diseases: Mechanisms, Implications, and Therapeutic Strategies
  4. Association between cardiometabolic index and thyroid function: insights from NHANES
  5. The Role of Lactate Metabolism in Tumors
  6. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
  7. Autophagy–senescence interplay in kidney disease: mechanistic insights and therapeutic potential
  8. Exposure–Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus
  9. Global burden of rheumatic vs non-rheumatic valvular heart disease, 1990–2021: a systematic analysis of the global burden of disease study
  10. Flavonoids in Metabolic Disease: A Narrative Review of Mechanisms and Therapeutic Potential
  11. Ribosome collisions and ZAKα activation: explores the therapeutic potential of metabolic diseases
  12. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study...
  13. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
  14. METTL3-mediated m6A methylation: implications for diabetes pathogenesis and therapeutic potential
  15. The role and therapeutic potential of exosome-mediated microRNAs regulatory networks in diabetic kidney disease
  16. Editorial: Novel approaches to diet, exercise, and drugs in childhood obesity and metabolic diseases
  17. Efficacy and safety benefits of HR17031 , a fixed‐ratio combination of INS068 and noiiglutide, versus its components alone in Chinese patients with ty...
  18. Pathophysiology of type 2 diabetes: A focus on the metabolic differences among southeast Asian, Chinese and Indian populations and how this impacts treatment
  19. Multimodal Neuroimaging of Brain Structure, Metabolism, and Function in Obesity: Current Landscape and Future Perspectives
  20. Editorial: Incretin-based therapies in the treatment of metabolic syndrome: expanding roles beyond weight management
  21. Global epidemiology and burden of type 2 diabetes in adults aged 55 and older: insights from 1990 to 2021
  22. Aging-Related Obesity: Unveiling Mitochondrial and Metabolic Dysfunction
  23. The global, regional, and national burden and attributable risk factors of Alzheimer's disease and other dementias, 1990-2021: A systematic analysis for the Global Burden of Disease Study
  24. Global epidemiology of type 1 diabetes in youth: 1990–2021 and projections to 2045
  25. Therapeutic Potential of Ginsenosides in the Treatment of Endocrine Diseases: Roles and Mechanisms
  26. Epigenetic regulation of nuclear receptors: Implications for endocrine-related diseases and therapeutic strategies
  27. Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990-2021 to 2045
  28. Nutritional Influences on Brown and Beige Adipocyte: Unraveling the Molecular Mechanisms and Metabolic Implications
  29. Associations between visceral adipose index, lipid accumulation products, and thyroid function parameters in U.S. Adults: analysis of NHANES data
  30. Exploring the Therapeutic Role of Pregnane X Receptor Activation in Acute Kidney Injury: Mechanisms and Clinical Implications
  31. Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease: Unraveling Connections and Advancing Therapies
  32. Glycerophospholipid and Sphingosine- 1-phosphate Metabolism in Cardiovascular Disease: Mechanisms and Therapeutic Potential
  33. KRAS Mutations in Cancer
  34. Updated Insights on Childhood Diabetes Epidemiology 2019-2021 and Projections to 2045
  35. Revolutionizing public health through digital health technology
  36. Exploring heparin’s protective mechanism against AGEs induced endothelial injury
  37. Editorial: Metabolic diseases and healthy aging: prevention and public health policy based on risk factors
  38. The influence of perceived formative assessment on the learning autonomy of medical students: the chain mediating role of psychological empowerment and positive academic emotions
  39. Empagliflozin alleviates obesity-related cardiac dysfunction via the activation of SIRT3-mediated autophagosome formation
  40. The complex link between the gut microbiome and obesity-associated metabolic disorders: Mechanisms and therapeutic opportunities
  41. Sestrin2 knockout exacerbates high-fat diet induced metabolic disorders and complications in female mice
  42. Emerging therapeutic landscape: Incretin agonists in chronic kidney disease management
  43. Metagenomic and metabolomic analysis showing the adverse risk–benefit trade-off of the ketogenic diet
  44. Exploring the multi-targeting phytoestrogen potential of Calycosin for cancer treatment: A review
  45. The impact of the senescent microenvironment on tumorigenesis: Insights for cancer therapy
  46. Combination of retagliptin and henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, active‐controlled, phase 3 trial
  47. Epidemiology of 369 diseases and injuries attributable to 84 risk factors: 1990–2019 with 2040 projection
  48. Environmental toxicology of bisphenol A: Mechanistic insights and clinical implications on the neuroendocrine system
  49. 20(S)-Ginsenoside Rh2 inhibits hepatocellular carcinoma by suppressing angiogenesis and the GPC3‐mediated Wnt/β‑catenin signaling pathway
  50. Editorial: Potential pathophysiological mechanisms underlying the comorbidity of depression and macrovascular diseases
  51. Unraveling the role of the FHL family in cardiac diseases: Mechanisms, implications, and future directions
  52. The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances
  53. Metabolic diseases and healthy aging: identifying environmental and behavioral risk factors and promoting public health
  54. BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases
  55. Changing trends of the diseases burden attributable to high BMI in Asia from 1990 to 2019: results from the global burden of disease study 2019
  56. Secreted frizzled-related protein 5: A promising therapeutic target for metabolic diseases via regulation of Wnt signaling
  57. Secreted frizzled-related proteins: A promising therapeutic target for cancer therapy through Wnt signaling inhibition
  58. Role of dysfunctional peri-organ adipose tissue in metabolic disease
  59. Editorial: Incretin agonists in the treatment of obesity
  60. Mechanisms and efficacy of traditional Chinese herb monomers in diabetic kidney disease
  61. Global, Regional, and National Epidemiology of Diabetes in Children From 1990 to 2019
  62. Astrocytes in Post-Stroke Depression: Roles in Inflammation, Neurotransmission, and Neurotrophin Signaling
  63. Editorial: Clinical and genetic determinants of diabetes and complications
  64. Optimizing glycation control in diabetes: An integrated approach for inhibiting nonenzymatic glycation reactions of biological macromolecules
  65. Editorial: The impact of adipose tissue dysfunction on cardiovascular and renal disease, Volume II
  66. Global, Regional, and National Burden of Pancreatic Cancer, 1990–2019: Results from the Global Burden of Disease Study 2019
  67. Editorial: Aging and chronic disease: public health challenge and education reform
  68. NTRK fusions in thyroid cancer: Pathology and clinical aspects
  69. Secular trends of epidemiologic patterns of chronic kidney disease over three decades: an updated analysis of the Global Burden of Disease Study 2019
  70. Advances in understanding the role and mechanisms of tumor stem cells in HER2-positive breast cancer treatment resistance (Review)
  71. Case report: Maturity-Onset Diabetes of the Young (MODY12) caused by ABCC8 gene mutations
  72. Global burden of non-alcoholic fatty liver disease in 204 countries and territories from 1990 to 2019
  73. Integrated multi-omics analyses reveal effects of empagliflozin on intestinal homeostasis in high-fat-diet mice
  74. Identification of Potential Indicators for Survival in Patients with Thyroid Cancer Based on Expression of FAM3 Members
  75. Advances in Understanding the Roles of Mesenchymal Stem Cells in Lung Cancer
  76. Calycosin induces autophagy and apoptosis via Sestrin2/AMPK/mTOR in human papillary thyroid cancer cells
  77. Irisin protects against obesity-related chronic kidney disease by regulating perirenal adipose tissue function in obese mice
  78. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2019
  79. Glutaminolysis and CD4+ T-cell metabolism in autoimmunity: From pathogenesis to therapy prospects
  80. Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease
  81. The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes
  82. COL1A1: A novel oncogenic gene and therapeutic target in malignancies
  83. The Therapeutic Potential of Mesenchymal Stem Cells in the Treatment of Diabetes Mellitus
  84. Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis
  85. Post-Translational Modifications of p53 in Ferroptosis: Novel Pharmacological Targets for Cancer Therapy
  86. Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development
  87. Utilizing Network Pharmacology and Molecular Docking Integrated Surface Plasmon Resonance Technology to Investigate the Potential Targets and Mechanisms of Tripterygium wilfordii against Pulmonary Artery Hypertension
  88. Novel HNF1A gene mutation in maturity-onset diabetes of the young: A case report
  89. Doctor of Public Health-Crisis Management and COVID-19 Prevention and Control: A Case Study in China
  90. Online Education Plight and Countermeasures for MBBS in Chinese Regional Medical Schools Based on the OBE Concept During COVID-19 Pandemic
  91. Editorial: The Impact of Adipose Tissue Dysfunction on Cardiovascular and Renal Disease
  92. Evodiamine induces ROS-Dependent cytotoxicity in human gastric cancer cells via TRPV1/Ca2+ pathway
  93. Comprehensive Analysis of Tumor Immune Microenvironment and Prognosis of m6A-Related lncRNAs in Lung Adenocarcinoma
  94. Association between serum Sestrin2 level and diabetic peripheral neuropathy in type 2 diabetic patients
  95. Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease
  96. A paradoxical role for sestrin 2 protein in tumor suppression and tumorigenesis
  97. Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis
  98. Identification of tRNA-derived Fragments and Their Potential Roles in Atherosclerosis
  99. Comprehensive overview of human serum albumin glycation in diabetes mellitus
  100. DL‑3‑n‑butylphthalide protects H9c2 cardiomyoblasts from ischemia/reperfusion injury by regulating HSP70 expression via PI3K/AKT pathway activation
  101. The analgesic efficacy of extracorporeal shock wave combined with percutaneous vertebroplasty in the treatment of osteoporotic thoracolumbar compression fractures in postmenopausal women
  102. Growth differentiation factor 11: a “rejuvenation factor” involved in regulation of age-related diseases?
  103. How to recognize and respond to viral re-positivity and disease relapse in patients with COVID-19
  104. Relationship between serum Dickkopf-1 and albuminuria in patients with type 2 diabetes
  105. Attaching clinical significance to COVID-19-associated diarrhea
  106. Identification of Potential Indicators for Survival in Patients With Thyroid Cancer Based on Mrna Expression Levels of Family With Sequence Similarity 3 Members
  107. Liraglutide improves obesity‐induced renal injury by alleviating uncoupling of the glomerular VEGF–NO axis in obese mice
  108. Epidemiology and clinical characteristics of 43 COVID-19 patients in Weifang, China
  109. Bioinformatic and biochemical findings disclosed anti-hepatic steatosis mechanism of calycosin
  110. SIRT1 agonism modulates cardiac NLRP3 inflammasome through pyruvate dehydrogenase during ischemia and reperfusion
  111. Novel insight into perirenal adipose tissue: A neglected adipose depot linking cardiovascular and chronic kidney disease
  112. Decreased shedding dipeptidyl peptidase 4 from membrane in Hashimoto's thyroiditis
  113. Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet–Induced Obese Mice
  114. Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2/HO-1 pathway
  115. Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway
  116. Identification of Potential Indicators for Survival in Patients with Thyroid Cancer Based on mRNA Expression Levels of Family with Sequence Similarity 3 Members
  117. Liraglutide improves vascular dysfunction by regulating a cAMP-independent PKA-AMPK pathway in perivascular adipose tissue in obese mice
  118. A Meta-Analysis of Pregnancy Outcomes with Levothyroxine Treatment in Euthyroid Women with Thyroid Autoimmunity
  119. AMPK: a balancer of the renin–angiotensin system
  120. AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
  121. AMPK: a therapeutic target of heart failure—not only metabolism regulation
  122. Screening of differentially expressed proteins from syncytiotrophoblast for severe early-onset preeclampsia in women with gestational diabetes mellitus using tandem mass tag quantitative proteomics
  123. Calycosin directly improves perivascular adipose tissue dysfunction by upregulating the adiponectin/AMPK/eNOS pathway in obese mice
  124. C1q/TNF-related protein 9 improves the anti-contractile effects of perivascular adipose tissue via the AMPK-eNOS pathway in diet-induced obese mice
  125. Irisin Improves Endothelial Dysfunction through Perivascular Adipose Tissue
  126. Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese mice
  127. Irisin improves endothelial function in obese mice through the AMPK-eNOS pathway
  128. Renal protective effects of induction of haem oxygenase-1 combined with increased adiponectin on the glomerular vascular endothelial growth factor-nitric oxide axis in obese rats
  129. Induction of Haemeoxygenase-1 Directly Improves Endothelial Function in Isolated Aortas from Obese Rats through the Ampk-Pi3k/Akt-Enos Pathway
  130. Induction of Haemeoxygenase-1 Improves FFA-Induced Endothelial Dysfunction in Rat Aorta
  131. The relationship between circulating irisin levels and endothelial function in lean and obese subjects
  132. Protective effects of adiponectin on uncoupling of glomerular VEGF–NO axis in early streptozotocin-induced type 2 diabetic rats
  133. Perirenal fat associated with microalbuminuria in obese rats
  134. Effect of high free fatty acids on the anti-contractile response of perivascular adipose tissue in rat aorta
  135. High FFA levels related to microalbuminuria and uncoupling of VEGF-NO axis in obese rats
  136. Sonographic evaluation of para- and perirenal fat thickness is an independent predictor of early kidney damage in obese patients
  137. The effect of telomerase activity on vascular smooth muscle cell proliferation in type 2 diabetes in vivo and in vitro
  138. Serum Fetuin-A Levels Related with Microalbuminuria in Diet-Induced Obese Rats
  139. Time–Action Profile of an Oral Enteric Insulin Formulation in Healthy Chinese Volunteers
  140. Correlation of ultrasonographic measurement of intrarenal arterial resistance index with microalbuminuria in nonhypertensive, nondiabetic obese patients
  141. Blockers of sulfonylureas receptor 1 subunits may lead to cardiac protection against isoprenaline-induced injury in obese rats
  142. Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK–eNOS pathways
  143. High free fatty acids level related with cardiac dysfunction in obese rats
  144. Effect of Aspirin on the Expression of Hepatocyte NF-κB and Serum TNF-α in Streptozotocin-Induced Type 2 Diabetic Rats
  145. Effect of polysaccharides of theEuphoria longan(Lour.) Steud on inflammatory response induced by focal cerebral ischemia/reperfusion injury in rats